{"intvolume":"         6","citation":{"chicago":"Siegert, Sandra, Peter Schnierle, and Barbara Schnierle. “Novel Anti-Viral Therapy: Drugs That Block HIV Entry at Different Target Sites.” <i>Mini-Reviews in Medicinal Chemistry</i>. Bentham Science Publishers, 2006. <a href=\"https://doi.org/10.2174/138955706776876267\">https://doi.org/10.2174/138955706776876267</a>.","apa":"Siegert, S., Schnierle, P., &#38; Schnierle, B. (2006). Novel anti-viral therapy: Drugs that block HIV entry at different target sites. <i>Mini-Reviews in Medicinal Chemistry</i>. Bentham Science Publishers. <a href=\"https://doi.org/10.2174/138955706776876267\">https://doi.org/10.2174/138955706776876267</a>","ista":"Siegert S, Schnierle P, Schnierle B. 2006. Novel anti-viral therapy: Drugs that block HIV entry at different target sites. Mini-Reviews in Medicinal Chemistry. 6(5), 557–562.","mla":"Siegert, Sandra, et al. “Novel Anti-Viral Therapy: Drugs That Block HIV Entry at Different Target Sites.” <i>Mini-Reviews in Medicinal Chemistry</i>, vol. 6, no. 5, Bentham Science Publishers, 2006, pp. 557–62, doi:<a href=\"https://doi.org/10.2174/138955706776876267\">10.2174/138955706776876267</a>.","short":"S. Siegert, P. Schnierle, B. Schnierle, Mini-Reviews in Medicinal Chemistry 6 (2006) 557–562.","ama":"Siegert S, Schnierle P, Schnierle B. Novel anti-viral therapy: Drugs that block HIV entry at different target sites. <i>Mini-Reviews in Medicinal Chemistry</i>. 2006;6(5):557-562. doi:<a href=\"https://doi.org/10.2174/138955706776876267\">10.2174/138955706776876267</a>","ieee":"S. Siegert, P. Schnierle, and B. Schnierle, “Novel anti-viral therapy: Drugs that block HIV entry at different target sites,” <i>Mini-Reviews in Medicinal Chemistry</i>, vol. 6, no. 5. Bentham Science Publishers, pp. 557–562, 2006."},"extern":1,"date_published":"2006-05-01T00:00:00Z","title":"Novel anti-viral therapy: Drugs that block HIV entry at different target sites","quality_controlled":0,"day":"01","publisher":"Bentham Science Publishers","month":"05","year":"2006","date_updated":"2021-01-12T06:53:15Z","publist_id":"5314","abstract":[{"lang":"eng","text":"Drugs that block the entry of human immunodeficiency virus type 1 (HIV-1) into host cells abrogate the establishment of a productive infection and should ideally diminish the chances of HIV-1 developing resistance. This review will give an overview of the mechanism by which the envelope glycoprotein mediates HIV-1 entry and will summarize current drug developments."}],"volume":6,"date_created":"2018-12-11T11:54:03Z","status":"public","author":[{"orcid":"0000-0001-8635-0877","first_name":"Sandra","last_name":"Siegert","full_name":"Sandra Siegert","id":"36ACD32E-F248-11E8-B48F-1D18A9856A87"},{"first_name":"Peter","last_name":"Schnierle","full_name":"Schnierle, Peter"},{"full_name":"Schnierle, Barbara S","first_name":"Barbara","last_name":"Schnierle"}],"issue":"5","publication_status":"published","publication":"Mini-Reviews in Medicinal Chemistry","_id":"1796","type":"journal_article","doi":"10.2174/138955706776876267","page":"557 - 562"}